Email this article 
Pollen allergy and household budget
- Authors: Mokronosova MA1, Mokronosova MA2
-
Affiliations:
- I. Mechnikov Research Institute for Vaccines and Sera, RAMS
- Issue: Vol 8, No 4 (2011)
- Pages: 79-83
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2011
- URL: https://rusalljournal.ru/raj/article/view/852
- DOI: https://doi.org/10.36691/RJA852
- ID: 852
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
The prevalence of the allergy to birch pollen is high in the middle part of russian Federation. the symptoms of allergic
intermittent rhinitis appears in the first decade and lasted during all life. the severity of the disease is aggravated annually.
the economic burden of allergic rhinitis includes direct, indirect and hidden costs. the indirect cost (disability and loss of
productivity, hypoallergenic life arrangements) exceeds direct costs many times. allergen specific immunotherapy by pollen
allergovaccines is unique kind of pathogenic management. asIt demonstrates significant improvement of the symptoms of
rhinitis and asthma, quality of life. one of the main problems is high costs of asIt. economical models used in investigations
on asIt cost effectiveness demonstrated lucre in the following 10 years of life after 3 year's course of asIt. In order to achieve
high clinical result it is necessary to follow european standard's guidance on specific immunotherapy strictly.
intermittent rhinitis appears in the first decade and lasted during all life. the severity of the disease is aggravated annually.
the economic burden of allergic rhinitis includes direct, indirect and hidden costs. the indirect cost (disability and loss of
productivity, hypoallergenic life arrangements) exceeds direct costs many times. allergen specific immunotherapy by pollen
allergovaccines is unique kind of pathogenic management. asIt demonstrates significant improvement of the symptoms of
rhinitis and asthma, quality of life. one of the main problems is high costs of asIt. economical models used in investigations
on asIt cost effectiveness demonstrated lucre in the following 10 years of life after 3 year's course of asIt. In order to achieve
high clinical result it is necessary to follow european standard's guidance on specific immunotherapy strictly.
Keywords
About the authors
M A Mokronosova
M A Mokronosova
I. Mechnikov Research Institute for Vaccines and Sera, RAMSI. Mechnikov Research Institute for Vaccines and Sera, RAMS
References
- Адо В.А., Астафьева Н.Г. Поллинозы: Повышенная чувствительность к пыльце. М., «Знание». 1991, с 224.
- A. Allergic rhinitis and its impact on asthma. WHO initiative, 2008.
- Blaiss M.S. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 2010, v. 31, No. 5, p. 375-380.
- Dykewicz M.S., Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann. Allergy Asthma Immunol. 1998, v. 81, p. 463-468.
- Demoly P., Allaert F.A., Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002, v. 57, p. 546-554.
- Blanc P.D., Trupin L., Eisner M. et al. The work impact of asthma and rhinitis: findings from a population-based survey. J. Clin Epidemiol. 2001, v. 54, p. 610-618.
- Kessler R.C., Almeida D.M., Berglund P., Stang P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann. Allergy Asthma Immunol. 2001, v. 87, p. 289-295.
- Lamb C.E., Ratner P.H., Johnson C.E., et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr. Med. Res. Opin. 2006, v. 22, p. 1203-1210.
- Malone D.C., Lawson K.A., Smith D.H. et al. A cost of illness study of allergic rhinitis in the United States. J. Allergy Clin. Immunol. 1997, v. 99, p. 22-27.
- Fireman P. Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Allergy Asthma Proc. 1997, v. 18, p. 63-67.
- Cockburn I.M., Bailit H.L., Berndt E.R., Finkelstein S.N. Loss of work productivity due to illness and medical treatment [In Process Citation]. J. Occup. Environ Med. 1999, v. 41, p. 948-953.
- Crystal-Peters J., Crown W.H., Goetzel R.Z., Schutt D.C. The cost of productivity losses associated with allergic rhinitis. Am. J. Manag. Care. 2000, v. 6, p. 373-378.
- Revicki D.A., Leidy N.K., Brennan-Diemer F. et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res. 1998, v. 7, p. 693-702.
- Schoenwetter W.F., Dupclay L.Jr., Appajosyula S. et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr. Med. Res. Opin. 2004, v. 20, p. 305-317.
- Bousquet J., Demoly P. Specific immunotherapy - an optimistic future. Allergy. 2006, v. 61, p. 1155-1158.
- The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy. 1989, v. 44, p. 369-379.
- Malling H. Immunotherapy. Position Paper of the EAACI. Allergy. 1988, v. 43 (Suppl.), p. 6.
- Malling H., Weeke B. Immunotherapy. Position Paper of the EAACI. Allergy. 1993, v. 14, p. 9-35.
- Malling H.J., Abreu-Nogueira J., Alvarez-Cuesta E. et al. Local immunotherapy. Allergy. 1998, v. 53, p. 933-944.
- Noon L. Prophylactic inoculation against hay fever. Lancet. 1911, p. 1572-1573.
- Schadlich P.K., Brecht J.G. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000, v. 17, p. 37-52.
- Omnes L.F., Bousquet J., Scheinmann P. et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Allerg. Immunol. (Paris). 2007, v. 39, p. 148-156.
- Brüggenjürgen B., Reinhold T., Brehler R. et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann. Allergy Asthma Immunol. 2008, v. 101 (3), p. 316-324.
- Alvarez-Cuesta E., Bousquet J., Canonica G.W. et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006, v. 61 (Suppl. 82), p. 1-20.
- Canonica G.W., Baena-Cagnani C.E., Bousquet J. et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A Statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.
- Bousquet J., Demoly P., Michel F.B. Specific immunotherapy in rhinitis and asthma. Ann. Allergy Asthma Immunol. 2001, v. 1 (Suppl. 1), p. 38-42.
- Wallner M., Briza P., Thalhamer J., Ferreira F. Specific immunotherapy in pollen allergy. Curr. Opin. Mol. Ther. 2007, v. 9 (2), p. 160-167.
- Nasser S., Vestenbaek U., Beriot-Mathiot A., Poulsen P.B. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008, v. 63 (12), p. 1624-1629.
- Creticos P.S., Van-Metre T.E., Mardiney M.R. et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J. Allergy Clin. Immunol. 1984, v. 73, p. 94-104.
- Bousquet J., Lockey R., Malling H. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53 (Suppl.), p. 54.
Supplementary files
